> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Remove Suicide Warning from GLP-1 Drugs: FDA
- URL: https://www.fdaweb.com/remove-suicide-warning-from-glp-1-drugs-fda/
- Published: 2026-01-13T12:00:00.000Z
- Updated: 2026-09-14T15:30:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160484

FDA says its evaluation did not find an increased risk of suicidal ideation or behavior in patients using glucagon-like peptide-1 (GLP-1) receptor agonist medications and thus companies should remove statements on suicidal ideation or behavior from the labeling. An agency [statement](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp?utm%5Fmedium=email&utm%5Fsource=govdelivery) says the affected products are Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide), and Lilly’s Zepbound (tirzepatide).

The notice says the labeling changes follow a “comprehensive FDA review that found no increased risk of suicidal ideation or behavior associated with the use of GLP-1 RA medications.”

At the time the three drugs were approved for a weight loss indication, FDA says, the labeling for each of the products included information in the Warnings and Precautions section about the potential risk of suicidal ideation and behavior.